课题基金 / 基金详情

Development of I-THP as New Medication for Drug Addiction (DP1)

Development of I-THP as New Medication for Drug Addiction (DP1)
I-THP作为戒毒新药的开发(DP1)
批准号:
8586877
负责人:
Jia Bei Wang
金额:
$76.95万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-30 至 2015-11-30

项目摘要

项目成果

Jia Bei Wang的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The foremost challenge to the effective treatment of cocaine addiction is the lack of FDA approved pharmacotherapy for this illicit drug. This DP1 proposal directly addresses this concern by performing clinical Phase I/II medication development and evaluation studies to determine the efficacy and safety of l-tetrahydropalmatine (l-THP) as an anti-addiction medication for cocaine dependence. l-THP, a major active single compound isolated from the Chinese herbal medicine Yanhusuo, has been used in clinical practice as an analgesic (commercial name: Rotundine) in China for more than 40 years. It has been reported that l-THP acts on dopamine (DA) receptors as a DP1 partial agonist/D2 antagonist and also interacts with D3 receptor. In addition, it has low affinity binding to alpha1 and 5HT1A receptors. l-THP attenuates cocaine self-administration and brain-stimulation reward in rats and relieves craving in heroin addicts. The mechanism for this action of l-THP is unknown. It could be related to its DA receptor activity, as the dopaminergic system plays a critical role in the activation of brain reward pathways. More importantly, it could be that l-THP binds to multiple monoamine receptors that provide efficacy as "a natural cocktail-like cocaine antagonist." Since, it is well known that cocaine non-selectively inhibits several monoamine transporters. Nevertheless, the unique pharmacological profile makes l-THP an excellent candidate for anti-addiction medication. The extensive animal and preclinical pharmacology and toxicity data resulting from decades of studies on l-THP in China provide a solid safety foundation for our proposed translational study. We plan to obtain IND approval of l-THP from the FDA, after which we will conduct clinical phase I and phase II trials. If this transition from animal studies to human clinical studies is successful, it will provide proof of concept that l-THP is an effective medication for cocaine addiction.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exploring the role of HINT1 protein in neuronal function
  • 批准号:
    8191532
  • 项目类别:
  • 资助金额:
    $23.03万
  • 财政年份:
    2011
  • 负责人:
    Jia Bei Wang
  • 依托单位:
Exploring the role of HINT1 protein in neuronal function
  • 批准号:
    8304358
  • 项目类别:
  • 资助金额:
    $19.19万
  • 财政年份:
    2011
  • 负责人:
    Jia Bei Wang
  • 依托单位:
Development of I-THP as New Medication for Drug Addiction (DP1)
Development of I-THP as New Medication for Drug Addiction (DP1)
  • 批准号:
    8337841
  • 项目类别:
  • 资助金额:
    $73.87万
  • 财政年份:
    2010
  • 负责人:
    Jia Bei Wang
  • 依托单位:
海外基金